Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (OTC: HALB) generates a steady stream of news centered on its healthcare technology initiatives, research collaborations, and funding developments. Investors and observers following HALB news can expect updates on traumatic brain injury (TBI) research, PTSD and mental health programs, AI-driven behavioral platforms, and partnerships with medical and technology organizations.
Recent press releases highlight Halberd’s work with Mississippi State University on a proprietary nasal spray intended to mitigate the effects of TBI, including plans for advanced Phase-2 animal studies. News items also cover the company’s acquisition and development of NeuroSense AI, a behavioral intelligence platform that combines ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring with Claude AI-powered interpretation for preclinical TBI and neurological research.
Another major theme in HALB news is its LDX and WatchDawg programs for PTSD, suicidal ideation, and related mental health challenges, particularly among veterans. Halberd and its partners report pilot study results using LDX-based therapies, nutraceuticals, yoga and meditation, and continuous wearable monitoring via Athena GTX’s technology. Announcements describe plans for larger clinical studies, solicitations for nephrologists and clinicians, and cooperative efforts with Athena Telemedicine Partners, LLC.
News releases also discuss funding and contract developments, including a substantial contract commitment involving Defense Atomics Corporation to support combined CRISPR/nanotechnology stem cell treatment with Halberd’s LDX protocol and WatchDawg monitoring. Readers of HALB news can use this page to follow progress on government contract proposals, private investment efforts, regulatory planning, and technical milestones in AI-powered healthcare platforms.
For anyone tracking HALB stock or its healthcare projects, the news feed provides context on how Halberd’s research programs, partnerships, and technology demonstrations evolve over time.
Halberd Corp. (OTC PINK: HALB) provides insights into its patented extracorporeal treatment for COVID-19 in a recent response from CEO William A. Hartman. The unique process aims to remove disease antigens from bodily fluids through a method akin to kidney dialysis, using complexing agents to attract and sequester these antigens. The company also holds provisional patents for multiple methods targeting COVID-19, emphasizing its distinct approach compared to conventional treatments. As a debt-free entity, Halberd is positioned to explore revolutionary medical techniques, although it faces potential regulatory scrutiny.
Halberd Corp. (OTC PINK: HALB) announced the appointment of Edson Brito to its Scientific Advisory Board. With extensive experience in sales and business development in the pharma sector, Brito aims to facilitate the advancement of COVID-19 treatments in international markets. Chairman William Hartman expressed confidence in Brito's expertise, particularly regarding the company's research and development efforts. Halberd holds exclusive rights to multiple provisional patents for COVID-19 treatment, emphasizing its commitment to addressing the pandemic.